Site Editor
Thomas Flaig, MD
Thomas Flaig, MD
Posted: Friday, May 19, 2023
After investigators accounted for tumor characteristics, early recurrence outcomes varied significantly by the specific hospital in which patients with presumed non–muscle-invasive bladder cancer underwent transurethral resection, among the 186 international sites taking part in the observational RESECT study. The differences could not be explained by “currently understood tumor features,” noted Veeru Kasivisvanathan, MD, of University College London, and colleagues at the American Urological Association (AUA) Annual Meeting 2023 (Abstract MP08-10) and published in The Journal of Urology. However, these differences may be because of “site-specific surgical techniques or perioperative practices.”
The team determined early recurrence using first-check cystoscopy. The included sites contributed 4,597 cases, with a mean of 25 each. They were located around the world: United Kingdom, 80; Europe, 59; North America, 18; Asia, 17; Africa, 7; South America, 3; and Oceania, 2.
The median recurrence rate per site was 12% for low-grade tumors and 27% for high-grade tumors. However, once the investigators controlled for tumor size, number, stage, and grade, the significant residual variation attributable to each site was significant (P < .0001). Further investigation should be undertaken to understand the differences in surgical procedural details and perioperative procedures that may help to explain these results, said Dr. Kasivisvanathan and co-investigators.
Disclosure: No disclosure information was provided.
JNCCN Spotlights
